Researchers have investigated the efficacy of IRI in CRC patients bearing different UGT1A1*28 genotypes [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31]. This evidence concerns the gene UGT1A1 and colorectal carcinoma.